Delivery Order SPE2DR25D3012-SPE2DR26F4D2T
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Lisinopril-HCTZ 20-25 mg tablets (500 count) with a ceiling value of $6,953.93 and ultimate completion date of December 10, 2025. This contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Lisinopril-HCTZ 20-25 mg tablets in a quantity of 500 units, with a ceiling value of $4,603.10. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and requires delivery by December 12, 2025, to the company's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of 1,000 tablets of Lisinopril-HCTZ 20-25 mg at a ceiling value of $1,344.35. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract has an ultimate completion date of August 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,248.47 delivery order to AmerisourceBergen Drug Corp for Lisinopril tablets, with an ultimate completion date of October 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. The delivery order will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,297.30 to AmerisourceBergen Drug Corp for the supply of 500 tablets of Lisinopril-Hydrochlorothiazide 20-25 mg, a combination antihypertensive medication. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on November 14, 2025, with an ultimate completion date of November 17, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of 1,000 tablets of Lisinopril-HCTZ 10-12.5 mg, a common antihypertensive medication used in military and federal healthcare systems. This firm fixed-price delivery order, valued at $1,199.34, represents a non-competitive set-aside award and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. The...
- The Defense Logistics Agency awarded a delivery order valued at $4,131.97 to AmerisourceBergen Drug Corp for 1,000 tablets of Lisinopril 40 mg, with an ultimate completion date of September 9, 2025. This non-set-aside contract employs firm fixed price terms and represents a direct fulfillment order under AmerisourceBergen's existing contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of 1,000 tablets of Lisinopril 10 mg, valued at $1,563.72. This is a firm fixed price delivery order with no set-aside designation, indicating the award was competitively bid. The contract is scheduled for ultimate completion on September 10, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Lisinopril is an ACE inhibitor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of 1,000 tablets of Lisinopril 40 mg, with a ceiling value of $2,041.70 and an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside delivery order uses firm fixed price pricing and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The order is for 1,000 units of the medication Lisinopril-HCTZ 20-25 mg tablets, with a potential value of $1,459.16. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4D2TDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of 500 tablets of Lisinopril-HCTZ 20-25 mg at a ceiling value of $4,598.58. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The order is scheduled for completion by December 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, serves as a prime contractor for the Defense Logistics Agency's Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems, including brand-name and generic medications, vaccines, and specialized medical commodities. The current delivery order for Lisinopril-HCTZ reflects the company's continued role as a primary pharmaceutical vendor supporting Department of Defense healthcare requirements through the DLA's competitive procurement process.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 12/9/25 |